EMA's restructured fee model may increase overall burden on drug firms
This article was originally published in Scrip
The European Medicines Agency is planning to restructure its current fee model so that there is "greater balance" between the money paid by pharmaceutical companies and the level of services provided by the agency. The proposed model, if approved, would effectively do away with the "tailor-made" approach currently being used – a move that has drawn major industry concern as it could increase the overall fee burden on drug companies.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’
Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.